综合征型基底细胞癌的基因组稳定性研究
该研究对比了基底细胞痣综合征(BCNS)相关基底细胞癌(BCC)与散发性BCC的基因组特征。发现BCNS-BCCs的突变负荷更低、UV诱变比例更小、基因组更稳定,且基线时功能性耐药SMO突变更少,这解释了其对SMO抑制剂缺乏内在耐药性。低肿瘤负荷的BCNS患者较高负荷者UV特征性体细胞突变和总体突变负荷显著更少,支持UV暴露在BCNS-BCC发生中的作用。
要点
- BCNS-BCCs较散发性BCCs突变负荷更低、基因组更稳定。
- BCNS-BCCs基线功能性耐药SMO突变较少,对SMO抑制剂更敏感。
- UV暴露可能驱动BCNS个体的BCC发生。
核心结论
- BCNS-BCCs较散发性BCCs具有更低的突变负荷、更低的UV诱变比例和更高的基因组稳定性,且基线功能性耐药SMO突变更少,这解释了其对SMO抑制剂缺乏内在耐药性。
研究设计与样本
- 研究对比了BCNS相关BCC与散发性BCC的基因组特征,并比较了低肿瘤负荷与高肿瘤负荷BCNS个体的突变特征。
主要发现
- 低肿瘤负荷BCNS个体较高负荷者UV特征性体细胞突变显著更少,总体体细胞突变负荷更低。
- BCNS-BCCs较散发性BCCs突变负荷显著更低、UV诱变比例更低、基因组稳定性更高。
- BCNS-BCCs基线时功能性耐药SMO突变较少。
临床怎么用
- BCNS-BCCs对SMO抑制剂反应更好且耐药少,支持其作为BCNS相关晚期BCC的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Basal cell cancers (BCCs) are characterized by upregulation of Hedgehog pathway through loss of PTCH1 or activation of SMO, and SMO inhibitors, such as vismodegib, are effective therapies for advanced BCCs. Although most BCCs are sporadic, rare individuals with basal cell nevus syndrome (BCNS) harbor germline defects in PTCH1 and develop up to hundreds of tumors that are histopathologically indistinguishable from sporadic BCCs. Interestingly, BCNS-BCCs are more responsive to SMO inhibitors than sporadic BCCs, with minimal development of resistance. Given differences in clinical course and therapy response, we sought to characterize BCCs in the setting of BCNS. We found that BCNS individuals with low tumor burden demonstrated significantly fewer UV signature somatic mutations and lower overall somatic mutational load compared to BCNS individuals with high burden, supporting a role of UV exposure in driving BCC development in BCNS individuals. However, compared with sporadic BCCs, BCNS-BCCs have a significantly lower mutational load, lower proportion of UV mutagenesis, increased genomic stability, and harbor fewer functionally resistant SMO mutations at baseline, explaining why BCNS-BCCs lack intrinsic resistance to SMO inhibitors. BCNS-BCCs appear to have reduced mutator phenotype compared with sporadic BCCs, which may contribute to their relatively more indolent clinical course and responsiveness to therapy.
引用
- Chiang A, Jaju PD, Batra P, et al. Genomic Stability in Syndromic Basal Cell Carcinoma. J Invest Dermatol. 2017. PMID: 29111235. doi:10.1016/j.jid.2017.09.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。